恩替卡韦联合a-2b干扰素抗乙肝病毒72周的疗效

目的：探讨恩替卡韦联合a-2b干扰素（a-2b IFN）治疗高病毒载量慢性乙型肝炎（CHB）72周时的临床疗效。方法：恩替卡韦（用药4周）联合a-2b干扰素治疗120例慢性乙型肝炎（ CHB）患者，疗程72周。检测120例患者在治疗48周、72周时HBV DNA及HBeAg、HBsAg的变化。结果：治疗48周后，120例患者的HBV DNA 不可检测率为93．3％，HBeAg阴转率为93．3％，HBeAg转换率56．7％，HBsAg阴转率0；治疗72周后，120例患者的HBV DNA不可检测率为97．5％，HBeAg阴转率为94．1％，HBeAg转换率70．8％，HBsAg阴转率33．3％。结论：恩替卡韦用药4周后联合a-2bIFN治疗高病毒载量CHB，随疗程由48周延长至72周，疗效提高，值得临床推广。

Effect of entec avir combined with a-2b interferon on treatment of chronic hepatitis B after th72 week

Objective：To explore the effect of entecavir combined with a -2b interferon （a-2b IFN）on the treatment of chronic hepatitis B（CHB） after 72weeks.Methods：120 patients of CHB were treated by entecavir （which had been used for the first 4 weeks alone） combining with a-2bIFN.The corse of the treatment was 72 weeks.the changs of serum HBV DNA levels ,HBeAg and HBsAg levels At 48th week and th72 week after treatment were monitored respectively of the 120 patients.R esults：after treatment for 48 weeks,the proportion of the 120 patients with undetectable serum HBV DNA was 93.3%;HBeAg loss was observed in 93.3%;HBeAg seroconversion rate reached to 56.7%;none lost HBsAg.At 72 weeks later, the proportion of the 120 patients with undetectable serum HBV DNA increased to 97.5%;the rate of HBeAg loss increased to 94.1%;HBeAg seroconversion rate increased to 70.8%;333.% of the 120 patients lost HBsAg.Conlu ison：Addition of IFNa-2b after entecavir monotherapy of 4 weeks could improve the efficacy when the therapy prolonged from 48 weeks to72 weeks in the treatment for the patients of CHB with high serum HBV DNA levels ,which was worth to popularize .